ArticleCancers2022

Durvalumab after Sequential High Dose Chemoradiotherapy versus Standard of Care (SoC) for Stage III NSCLC: A Bi-Centric Trospective Comparison Focusing on Pulmonary Toxicity.

Romana Wass et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.